Isomorphic Labs, the London-based AI drug discovery company, has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital.

The company announced the round on 17 November 2026. Andreessen Horowitz (a16z) and several other new investors joined, alongside continued significant investment from Alphabet.

All existing investors took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Isomorphic has not disclosed a valuation for the round.

What the money is for

Isomorphic is building medicines designed with AI. Its core asset is a proprietary drug design engine called IsoDDE, which the company says works across several therapeutic areas and drug modalities.

According to the full news release, the funding will go towards:

  • maturing IsoDDE and expanding into new areas of biology
  • building a partner ecosystem
  • building global AI-led bioengineering infrastructure
  • setting up AI-first translational and clinical development as candidates move towards trials

The company also reports positive preclinical results from internal programmes in oncology and immunology, and from work with partners. It says this sets the stage for clinical entry.

What the founder and lead investor said

Sir Demis Hassabis, founder and CEO of Isomorphic, said the round lets the company accelerate its progress. He pointed to foundational biology models, a deeper understanding of systemic disease, and driving its first therapeutic programmes towards clinical trials.

Neil Mehta of Greenoaks described discovering and developing new medicines as an optimisation challenge of almost infinite scale.

How this follows the Series B

This is a second very large raise in a short space of time. Bizztor covered the company's earlier $2.1 billion Series B led by Thrive Capital in May, in which the UK Sovereign AI Fund also invested.

The UK Sovereign AI Fund taking part again matters for the UK. A company headquartered in London, with offices in Cambridge, Massachusetts and Lausanne, is still drawing very large cheques.

What it means for UK founders

For founders building in biotech or AI, the signal is that deep technical bets can still attract global capital to a UK base. Most rounds are far smaller, and Bizztor's UK startup funding data puts them in context.

Other UK biotechs are raising at an earlier stage, and Bizztor's UK healthtech funding data shows the wider picture. Bizztor has reported on Oyster Therapeutics' $60M Series A for an oral Alzheimer's tau degrader, and on Neobe's seed round for engineered cancer bacteria.

Isomorphic was founded in 2021 and is led by Hassabis, who is also CEO of Google DeepMind. Max Jaderberg is its president.